SEATTLE, Jan. 12, 2015 /PRNewswire/ -- Adaptive Biotechnologies Corporation announced today that Chad Robins, Founder and Chief Executive Officer, will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12th, 2015 at 10:30am PST in Elizabethan C/D. Mr. Robins will discuss the Company's recent acquisition of Sequenta, and the combined company's vision to leverage the power of sequencing an individual's adaptive immune system to change the course of medicine.
Additionally, Mr. Robins will join the panel, "Harnessing the Power of Next Gen Sequencing (View from Industry)" with Randy Scott (Invitae CEO), George Yucanopolos (Regeneron CSO) and Mike Pellini (Foundation Medicine CEO). The panel will be on Monday, January 12th, 2015 at 5:00pm PST.
Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages next generation sequencing to profile T-cell and B-cell receptors. This breakthrough enables in-depth characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis and monitoring of cancer patients.
Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology, which is now available to facilitate the integration of immunosequencing into research centers. For additional information about Adaptive, please visit www.adaptivebiotech.com.
SOURCE Adaptive Biotechnologies Corp.